Other Information.
−Removed: None of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted , modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K, except as follows:
−Removed: On March 26, 2024 , Sean A.
−Removed: McCarthy , our Chief Executive Officer , terminated a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) and originally adopted on June 01, 2023 , for the sale of up to 109,768 shares of the Company’s common stock until February 07, 2025 .
CytomX Therapeutics, Inc.
2 unchanged sentences
Amended and Restated Certificate of Incorporation.
−Removed: Certificate of Amendment to Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc.
Amended and Restated Bylaws of CytomX Therapeutics, Inc., effective March 20, 2024.
1 unchanged sentence
Specimen Common Stock Certificate
−Removed: Amendment No.
−Removed: 4 to the Collaboration and License Agreement, dated as of March 28, 2024, by and between CytomX Therapeutics, Inc.
−Removed: and Amgen, Inc.
−Removed: Certification of Chief Executive Principal required by Rule 13a-14(a) or Rule 15d-14(a).
−Removed: Certification of Chief Financial Principal required by Rule 13a-14(a) or Rule 15d-14(a).
+Added: Amendment No.1 to the Collaboration and License Agreement effective as of June 28, 2024 by and between CytomX Therapeutics, Inc.
+Added: and Regeneron Pharmaceuticals, Inc.
+Added: Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
+Added: Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
13 unchanged sentences
CytomX Therapeutics, Inc.
+Added: August 8, 2024
Chief Executive Officer and Chairman
(Principal Executive Officer)
+Added: August 8, 2024
/s/ Christopher W.
Christopher W.
−Removed: Senior Vice President, Finance and Accounting
+Added: Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.